Victoria Scott, MD
Urogynecology and Reconstructive Pelvic Surgery · Los Angeles, CANPI 1275822322
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,323 of the $5,135 with a category attached, or 84.2%. Medtronic accounts for 60.2% of it on its own, with 21 other manufacturers making up the rest.
Across 121 payments — averaging $42.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Coloplast$256
- Caldera Medical, Inc$255
- AbbVie$251
- Boston Scientific$169
- Astellas Pharma Global Development$140
- plus $972 from 16 others
Across 16 payments — averaging $2647.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$42K
What the payments were for
- Grants$1212%
- Travel & lodging$62112%
- Food & beverage$4,32384%
- Education$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 58 | $3,092 |
| Coloplast | 13 | $256 |
| Caldera Medical, Inc | 1 | $255 |
| AbbVie | 8 | $251 |
| Boston Scientific | 2 | $169 |
| Astellas Pharma Global Development | 2 | $140 |
| Procept Biorobotics Corporation | 2 | $137 |
| Progenics Pharmaceuticals, Inc. | 6 | $133 |
| Axonics, Inc. | 2 | $122 |
| Johnson & Johnson | 5 | $89 |
| Sumitomo Pharma America, Inc. | 5 | $85 |
| Endo Pharmaceuticals Inc. | 3 | $64 |
| Blue Earth Diagnostics | 2 | $61 |
| Smith+Nephew | 2 | $60 |
| Endo USA, Inc. | 2 | $50 |
| Teleflex LLC | 2 | $46 |
| Mimedx Group, Inc. | 1 | $27 |
| TG Therapeutics, Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| Urogen Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$1,809
- ALTAVIVA$269
- AquaBeam Robotic System$123
How this compares
$5,135 in reported general payments places this provider in the 60th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 539 | $321,872 |
| GemtesaVibegron | 349 | $269,263 |
| Estradiol | 533 | $33,850 |
| Methenamine Hippurate | 296 | $22,469 |
| Tolterodine Tartrate ErTolterodine Tartrate | 67 | $6,904 |
| Mirabegron ErMirabegron | 15 | $3,943 |
| Solifenacin Succinate | 91 | $3,850 |
| Tamsulosin Hcl | 199 | $2,321 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 189 | $2,318 |
| NitrofurantoinNitrofurantoin Macrocrystal | 136 | $1,936 |
| Trimethoprim | 40 | $1,549 |
| Finasteride | 94 | $1,136 |
| Potassium Citrate ErPotassium Citrate | 18 | $631 |
| Clobetasol Propionate | 41 | $586 |
| Oxybutynin Chloride ErOxybutynin Chloride | 40 | $557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $18 | $321,872539 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $85 | $269,263349 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
Other urogynecology and reconstructive pelvic surgery in Los Angeles
- Tanaz FerzandiLos Angeles$60K
- Christopher TarnayLos Angeles$41K
- Anne AckermanLos Angeles$32K
- Darlene MorrisseyLos Angeles$10K
- Yoko BeanLos Angeles$9K
- Thinh DuongLos Angeles$5K
- Victor VelascoLos Angeles$5K
- Andrey PetrikovetsLos Angeles$5K
- Atieh NovinLos Angeles$5K
- Michele TorosisLos Angeles$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.